Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multicenter, Open-Label, Safety and Pharmacokinetic Study of Orally Administered Ivosidenib in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment

Next Previous
Trial Profile

A Phase 1, Multicenter, Open-Label, Safety and Pharmacokinetic Study of Orally Administered Ivosidenib in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ivosidenib (Primary)
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Servier

Most Recent Events

  • 13 Feb 2026 Status changed from not yet recruiting to recruiting.
  • 14 Jan 2026 Planned End Date changed from 1 Jul 2028 to 31 Aug 2028.
  • 14 Jan 2026 Planned primary completion date changed from 1 Jul 2028 to 31 Jul 2028.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top